In a randomised phase 1b/2 trial of 152 patients with untreated advanced oesophageal cancer, confirmed objective response was 67.7% with tiragolumab plus atezolizumab and chemotherapy, 53.8% with atezolizumab and chemotherapy, and 47.8% with chemotherapy alone.
RCTn = 152
Sun et al. First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial